The relationship between acotinib/acabrutinib and Tagrisso

Acalabrutinib/Acalabrutinib and Osimertinib are two different anti-tumor drugs. They differ in drug type, mechanism of action, indications and clinical application.

From the perspective of drug type and mechanism of action, acotinib is a BTK inhibitor developed by AstraZeneca (ASTRAZENECA) and is a second-generation BTK inhibitor. It inhibits the function of the BTK gene (protein) and interrupts the B cell receptor signaling pathway, thereby inhibiting the growth of cancer cells with B cell characteristics. Tagrisso (chemical name: osimertinib mesylate tablets) is a third-generation EGFR tyrosine kinase inhibitor (TKI) that blocks the growth and spread of tumor cells by inhibiting the activity of EGFR mutant proteins.

In terms of indications, acotinib is mainly used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). According to clinical studies, acotinib has shown good efficacy in adult patients with MCL who have received at least one treatment in the past, with an objective response rate as high as 81%, a median progression-free survival (PFS) of 22 months, and a median overall survival (OS) of 59.2 months. Tagrisso is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as well as NSCLC patients who have previously experienced disease progression during or after EGFR TKI treatment and have been confirmed to have EGFRT790M mutation-positive NSCLC patients.

In clinical application, both acotinib and Tagrisso have shown good efficacy and safety. However, due to their different mechanisms of action and indications, selection needs to be based on the specific conditions of the patient in practical applications.